Table 5.

Medication protocols applied in 1234 patients

Medication ProtocolNo. of PatientsNo. of PeriodsCotreated with RAS Antagonists (%)Cotreated with Oral Steroids (%)Treatment Duration (mo)Response to Therapy
Partial Remission N/Ninfo (%)Complete Remission N/Ninfo (%)
RAS antagonists only62395063.35.2 (1.9–17.1)109/531 (20.5)141/531 (26.6)
Oral steroids only72211192.0 (1.4–4.7)53/567 (9.3)62/567 (10.9)
Steroid pulses541111451.072.40.1 (0.1–0.9)42/279 (15.1)25/279 (9.0)
CPH (oral or pulse)27333639.092.02.5 (1.6–3.0)11/131 (8.4)22/131 (16.8)
CNI806121070.789.58.3 (3.0–23.0)153/707 (21.6)311/707 (44.0)
MMF17721980.471.76.7 (3.0–14.9)19/148 (12.8)57/148 (38.5)
CNI + MMF13716781.476.07.7 (3.0–23.9)26/119 (21.8)57/119 (47.9)
Rituximab799187.976.90.0 (0.0–4.6)10/66 (15.2)29/66 (43.9)
  • Treatment duration is given as median and interquartile range. Renin angiotensin system (RAS) antagonists are angiotensin-converting enzyme inhibitor and/or angiotensin type 1 receptor blocker. CPH, cyclophosphamide; CNI, calcineurin inhibitor (ciclosporin A or tacrolimus); MMF, mycophenolate-mofetil.